The Centers for Disease Control and Prevention (CDC)1 and the World Health Organization (WHO)2 have highlighted surveillance of the following Omicron lineages:
(1) BA.2.3.20, BA.2.75, BA.4.6, BA.5, BA.5.2.6, BF.7, BQ.1, BQ.1.1, and XBB
Additionally, six other variants have been under continued surveillance despite their lower prevalence:
(2) Delta (also known as B.1.617.2, all sublineages) first detected in India,
(3) Alpha (also known as B.1.1.7, all sublineages) first detected in the United Kingdom,
(4) Beta (also known as B.1.351, all sublineages) first detected in South Africa,
(5) Gamma (also known as P.1, all sublineages) first detected in Japan/Brazil,
(6) Lambda (also known as C.37, all sublineages) first detected in Peru,
(7) Mu (also known as B.1.621, all sublineages) first detected in Colombia
Lucira Health performs routine surveillance of emerging SARS-CoV-2 strains by periodically evaluating in silico reactivity against sequence databases. These evaluations have shown that these variants are reactive to the Lucira COVID-19 Check-It and All-In-One Test Kits. The Lucira Health assay targets two non-overlapping regions of the SARS-CoV-2 genome. The detection regions are unaffected by the mutations in the spike protein of SARS-CoV-2 in the variant strains.
Lucira Health will continue to monitor the situation with emerging variants of SARS-CoV-2.
If you have any questions on the above, please reach out to Technical Support at